• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer.

作者信息

Yu Zhigang

机构信息

Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, China.

出版信息

Transl Breast Cancer Res. 2023 Nov 22;5:5. doi: 10.21037/tbcr-23-39. eCollection 2024.

DOI:10.21037/tbcr-23-39
PMID:38751685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11093077/
Abstract
摘要

相似文献

1
Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer.替雷利珠单抗：早期三阴性乳腺癌的有效治疗选择。
Transl Breast Cancer Res. 2023 Nov 22;5:5. doi: 10.21037/tbcr-23-39. eCollection 2024.
2
Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer.早期三阴性乳腺癌新辅助/辅助免疫治疗的前景
Transl Breast Cancer Res. 2023 Jan 31;4:6. doi: 10.21037/tbcr-23-4. eCollection 2023.
3
Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review.替雷利珠单抗联合化疗治疗转移性三阴性乳腺癌的最佳反应：病例报告及文献综述
Front Oncol. 2024 Mar 28;14:1328844. doi: 10.3389/fonc.2024.1328844. eCollection 2024.
4
Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.免疫检查点抑制剂治疗三阴性乳腺癌：从免疫机制到临床证据。
Int Immunopharmacol. 2021 Sep;98:107876. doi: 10.1016/j.intimp.2021.107876. Epub 2021 Jun 17.
5
Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer.免疫检查点抑制剂：三阴性乳腺癌的新治疗线。
Cancer Treat Res. 2023;188:29-62. doi: 10.1007/978-3-031-33602-7_2.
6
The landscape of systemic therapy for early stage triple-negative breast cancer.早期三阴性乳腺癌的系统治疗全景。
Expert Opin Pharmacother. 2022 Aug;23(11):1291-1303. doi: 10.1080/14656566.2022.2095902. Epub 2022 Jul 25.
7
Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer.循环肿瘤DNA（ctDNA）突变对晚期三阴性乳腺癌免疫检查点抑制剂疗效的潜在预测价值。
Front Genet. 2023 Mar 16;14:1125970. doi: 10.3389/fgene.2023.1125970. eCollection 2023.
8
Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.新辅助免疫检查点抑制剂在早期三阴性乳腺癌中的疗效和安全性：系统评价和荟萃分析。
J Cancer Res Clin Oncol. 2021 Nov;147(11):3369-3379. doi: 10.1007/s00432-021-03591-w. Epub 2021 Mar 21.
9
The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.免疫检查点抑制剂在三阴性乳腺癌治疗中的不断演变的角色。
Clin Adv Hematol Oncol. 2021 May;19(5):305-315.
10
Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.免疫检查点抑制剂在转移性或早期三阴性乳腺癌一线治疗中的应用：一项系统评价和网络荟萃分析。
Front Endocrinol (Lausanne). 2023 May 9;14:1137464. doi: 10.3389/fendo.2023.1137464. eCollection 2023.

本文引用的文献

1
The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity.肿瘤微环境在耐药性中的作用：揭示乳腺癌异质性的新兴技术
Front Oncol. 2023 May 17;13:1170264. doi: 10.3389/fonc.2023.1170264. eCollection 2023.
2
PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study.实体瘤中基于程序性死亡受体1（PD-1）抑制剂的不良事件：一项回顾性真实世界研究。
Front Pharmacol. 2022 Nov 9;13:974376. doi: 10.3389/fphar.2022.974376. eCollection 2022.
3
Triple negative breast cancer: Pitfalls and progress.
三阴性乳腺癌：陷阱与进展
NPJ Breast Cancer. 2022 Aug 20;8(1):95. doi: 10.1038/s41523-022-00468-0.
4
Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.替雷利珠单抗：一种修饰的抗肿瘤程序性死亡受体 1 抗体。
Cancer Control. 2022 Jan-Dec;29:10732748221111296. doi: 10.1177/10732748221111296.
5
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification.2022年中国临床肿瘤学会乳腺癌（CSCO BC）指南：分层与分类
Cancer Biol Med. 2022 Jun 29;19(6):769-73. doi: 10.20892/j.issn.2095-3941.2022.0277.
6
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.三阴性、早期高危及局部晚期乳腺癌新辅助治疗（无论是否联合阿替利珠单抗）的病理完全缓解（pCR）：NeoTRIP米开朗基罗随机研究
Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. Epub 2022 Feb 17.
7
Immunotherapy for early triple negative breast cancer: research agenda for the next decade.早期三阴性乳腺癌的免疫治疗：未来十年的研究议程。
NPJ Breast Cancer. 2022 Feb 18;8(1):23. doi: 10.1038/s41523-022-00386-1.
8
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌无事件生存。
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
9
Pathogenesis of Triple-Negative Breast Cancer.三阴性乳腺癌的发病机制。
Annu Rev Pathol. 2022 Jan 24;17:181-204. doi: 10.1146/annurev-pathol-042420-093238.
10
Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.三阴性乳腺癌的肿瘤突变负担和免疫浸润特征：全基因组高通量数据分析。
Front Immunol. 2021 Apr 21;12:650491. doi: 10.3389/fimmu.2021.650491. eCollection 2021.